As a world-leading medical technology company, ZEISS drives progress in medicine, enabling doctors to achieve the best possible outcomes for their patients. Our vision is to become the partner of choice for healthcare providers in our segments and to improve the quality of life through our innovations by contributing to progress in medicine. Our products and solutions aim to help physicians to improve patient outcomes and their patients’ quality of life.

To accomplish this, we must continue to expand our leading market position by developing innovative high-tech products and solutions and aligning our success to that of solving our customer’s greatest needs.

One example; is the acquisition of IanTECH, Inc. in December of 2018. IanTECH, headquartered in Reno, Nevada a privately held company focused on technology solutions for micro-interventional cataract surgery.

Cataract surgery has been dependent on phaco technology for over 50 years. ZEISS believes that the market needs a fresh innovative approach in the field of phaco and IanTECH’s surgical technology is designed to change the future of managing cataracts.

Combined with ZEISS’ leading portfolio of equipment and consumables in cataract surgery, this acquisition advances the portfolio of Surgical Ophthalmology solutions provided by ZEISS and further positions the Company as a global innovation leader and solution provider in the full ophthalmic spectrum of ophthalmology.

“This acquisition enables us to complete our solutions portfolio for surgical ophthalmology and reposition ourselves as a global solutions provider for the entire range of ophthalmic care.” said Jim Mazzo, Global President of Ophthalmic Devices at Carl Zeiss Meditec. “Acquiring great entrepreneurial ideas and integrating them into the company expands opportunities for research and development.”

IanTECH is now integrated into the ZEISS Group under the name of Carl Zeiss Meditec Cataract Technology, Inc. and markets the ZEISS miLOOP.